Treatment of leukemia in relapse after bone marrow transplantation

T. De Witte, T. Schattenberg, R. H. Collins, J. W. Fay, R. Champlin, S. Giralt

Research output: Contribution to journalLetterpeer-review

2 Scopus citations


To the Editor: The prognosis of patients with a relapse of leukemia within the first year after allogeneic bone marrow transplantation is dismal. Giralt et al. (Sept. 9 issue)1 described seven patients whose leukemia had relapsed after allogeneic bone marrow transplantation. All were treated with granulocyte colony-stimulating factor (filgrastim) to induce terminal differentiation of the leukemic clone, selectively stimulate donor hematopoietic cells, and enhance the graft-versus-leukemia reaction. Three of the seven patients had a complete response, with reestablishment of hematopoiesis of donor origin. We observed such a trend toward a lower relapse rate in patients treated with recombinant granulocyte-macrophage colony-stimulating.

Original languageEnglish (US)
Pages (from-to)645-646
Number of pages2
JournalNew England Journal of Medicine
Issue number9
StatePublished - Mar 3 1994

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Treatment of leukemia in relapse after bone marrow transplantation'. Together they form a unique fingerprint.

Cite this